Question

In: Statistics and Probability

Use SAS to answer the question: A drug company tested three formulations of a pain relief...

Use SAS to answer the question:

A drug company tested three formulations of a pain relief medicine for migraine headache sufferers.
For the experiment 27 volunteers were selected and 9 were randomly assigned to one of three drug
formulations. The subjects were instructed to take the drug during their next migraine headache episode
and to report their pain on a scale of 1 to 10 (10 being most pain)

Drug A: 4 5 4 3 2 4 3 4 4
Drug B: 6 8 4 5 4 6 5 8 6
Drug C: 6 7 6 5 7 5 6 6 5

a) Test if the means for all three drug groups are equal.
(b) If the means are not equal, perform a multiple comparison at the 0.01 level.
(c) Create a contrast to compare group B against the mean of group A and group C at the 0.01 level.

Solutions

Expert Solution

We want to test the effect of drug A. B and C on headache pain.

a)

Testing of Hypothesis:

H0: The average effect of all three drugs is the same.

against,

H1: The average effect of all three drugs is different.

One way ANOVA in SAS:

data a;

input drug $ value;

datalines;

A 4

A 5

A 4

A 3

A 2

A 4

A 3

A 4

A 4

B 6

B 8

B 4

B 5

B 4

B 6

B 5

B 8

B 6

C 6

C 7

C 6

C 5

C 7

C 5

C 6

C 6

C 5

;

run;

proc anova data=a;

class drug;

model value=drug;

quit;

Decision Rule:

If p-value greater than 0.01 level of significance then accept the null hypothesis.

From the above ANOVA the p-value (0.0003) < 0.01

so we reject the null hypothesis.

i.e. Effects of all drugs are not the same.

b) For checking the individual pairwise effects of drugs we want to use paired t-test here by using SAS

The syntax for the t-test in SAS:

proc t test plots = all;

var drug $ value;

run;

The hypothesis for the t-test is,

H0: The effect of both drugs A and B is the same.

against,

H1: The effect of both drugs A and B are different.

Test Statistics:

for Drug A and B:

T = -6.0083

p-value = 0.000320

p-value < 0.01, so reject the null hypothesis at 1 % level of significance

i.e. The effect of both drugs A and B are different.

for Drug A and C:

T = -5.5470

p-value = 0.000542

the p-value < 0.01, to reject the null hypothesis at 1 % level of significance

i.e. The effect of both drugs A and C are different.

for Drug B and C:

T = -0.2062

p-value = 0.8417

the p-value > 0.01, to accept the null hypothesis at 1 % level of significance

i.e. The effect of both drugs B and C are the same.

>>>>>>>>>>>>>>> Best Luck >>>>>>>>>>>>>>


Related Solutions

A drug company tested three formulations of a pain relief medicine for migraine headache sufferers. For...
A drug company tested three formulations of a pain relief medicine for migraine headache sufferers. For the experiment 27 volunteers were selected and 9 were randomly assigned to one of three drug formulations. The subjects were instructed to take the drug during their next migraine headache episode and to report their pain on a scale of 1 to 10 (10 being most pain). Drug A Drug B Drug C 4 6 6 5 8 7 4 4 6 3 5...
Problem 1. A drug company tested three formulations of a pain relief medicine for migraine headache...
Problem 1. A drug company tested three formulations of a pain relief medicine for migraine headache sufferers. For the experiment 27 volunteers were selected and 9 were randomly assigned to one of three drug formulations. The subjects were instructed to take the drug during their next migraine headache episode and to report their pain on a scale of 1 to 10 (10 being most pain).              Drug A 4 5 4 3 2 4 3 4 4              Drug B 6 8...
Use SPSS for this Application Exercise: A pharmaceutical company tested three formulations of a pain relief...
Use SPSS for this Application Exercise: A pharmaceutical company tested three formulations of a pain relief medicine for migraine headache sufferers. Volunteers were selected and randomly assigned to one of the three drug formulations. The volunteers were instructed to take the drug during their next migraine headache episode and to report their pain on a scale of 1 to 10 (10 being most pain). The data are below. What can be concluded with ? = 0.05? formulation A formulation B...
A pharmaceutical company tested three formulations of a pain relief medicine for migraine headache sufferers. For...
A pharmaceutical company tested three formulations of a pain relief medicine for migraine headache sufferers. For the experiment, 88 volunteers were randomly assigned to one of three drug formulations. The subjects were instructed to take the drug during their next migraine headache episode and to report their pain level on a Likert scale of 1 (no pain) to 10 (extreme pain) 30 minutes after taking the drug. Is there a significant difference in the mean pain level for at least...
A pharmaceutical company tested three formulations of a pain relief medicine for migraine headache sufferers. For...
A pharmaceutical company tested three formulations of a pain relief medicine for migraine headache sufferers. For the experiment, 27 volunteers were selected and 9 were randomly assigned to one of three drug formulations. The subjects were instructed to take the drug during their next migraine headache episode and to report their pain on a scale of 1 = no pain to 10 = extreme pain 30 minutes after taking the drug. a. Identify the response variable for this experiment. __________________________________(2)...
A pharmaceutical company tested four formulations of a pain relief medicine for migraine headache sufferers. For...
A pharmaceutical company tested four formulations of a pain relief medicine for migraine headache sufferers. For the experiment, 32 volunteers were selected and 8 were randomly assigned to one of four drug formulations. The subjects were instructed to take the drug during their next migraine headache episode and to report the time it needs for their pain to go away after taking the drug. Carry out an appropriate test to see if there are any mean differences in pain relief...
A new drug for pain relief is being tested within a given palliative care population. The...
A new drug for pain relief is being tested within a given palliative care population. The new drug is being compared to an already approved pain relief drug that is commonly used in providing palliative care to patients who experience chronic severe pain. Assume the patients are asked to rate the pain on a scale from 1 to 10, and the data presented below was obtained from a small study designed to compare the effectiveness of the two drugs. Set...
A drug company is marketing a new pain relief formula in 800 mg. tablets. The company...
A drug company is marketing a new pain relief formula in 800 mg. tablets. The company claims that on the average 2.6 of the tablets will eliminate a migraine headache. A neurologist asks 36 of her patients with migraines to keep track of how many of the new tablets are needed to get relief from their next migraine. Her patients have an average of 3.1 tablets with a standard deviation of 1.1. Can the neurologist conclude at the 0.05 level...
Use the following data set – Pain Relief Study - to answer this series of questions....
Use the following data set – Pain Relief Study - to answer this series of questions. Participant Before Treatment After Treatment 1 90 80 2 70 50 3 60 60 4 90 70 5 70 60 6 50 40 7 70 60 Patients in a drug trial rate their pain before treatment and after treatment. Higher scores equate to higher levels of reported pain with a maximum possible score of 100. 11.1 Calculate MD for the Pain Relief Study 11.2...
The length of pain relief from the drug Tramadol is known to be normally distributed. The...
The length of pain relief from the drug Tramadol is known to be normally distributed. The pharmaceutical company that makes Tramadol claims that the average pain relief lasts longer than 4 hours. A random sample of 15 patients on Tramadol had a mean of 4.28 hours and a standard deviation of 0.5 hours. a) State the hypotheses b) State the rejection region for 훼=0.025 c) Perform a Student’s T-test and state your conclusion. d) The p-value for this sample will...
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT